Targeting the β secretase BACE1 for Alzheimer's disease therapy.

@article{Yan2014TargetingT,
  title={Targeting the β secretase BACE1 for Alzheimer's disease therapy.},
  author={Riqiang Yan and Robert Vassar},
  journal={The Lancet. Neurology},
  year={2014},
  volume={13 3},
  pages={319-29}
}
The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1 (BACE1), initiates the production of the toxic amyloid β (Aβ) that plays a crucial early part in Alzheimer's disease pathogenesis. BACE1 is a prime therapeutic target for lowering cerebral Aβ concentrations in Alzheimer's disease, and clinical development of BACE1 inhibitors is being intensely pursued. Although BACE1 inhibitor drug development has proven challenging, several promising BACE1 inhibitors have… CONTINUE READING